Skip to content
mapperlab
← Dashboard
Stock

CABA

CABALETTA BIO, INC.
Latest close $3.295 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
5
27 funds tracked
Ever held
8
Current + past
New this quarter
1
Exited this quarter
1

Marquee-fund ownership over time

May 15, 2024Feb 13, 2025Nov 14, 2025May 15, 2026
Now
5

This quarter's activity

New positions opened

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Two Sigma Investments$4.38$3.29-25%
Millennium Management$4.38$3.29-25%
D.E. Shaw re-entered$3.78$3.29-13%
Point72 Asset Management re-entered$3.78$3.29-13%
Renaissance Technologies$2.70$3.29+22%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Citadel Advisors 2× in & out→ $3.31+83%
AQR Capital Management→ $2.31+28%
Duquesne Family Office—+0%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Cabaletta Bio, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
6
Filings · last 90d
14
Total on file
116
Recent SEC buffer
Most recent
Mar 2, 2026

30d / 90d windows measured from Mar 2, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 116 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · CABALETTA BIO, INC.

Annual figures sourced directly from CABALETTA BIO, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Net income
-$167.86M
FY2025-45% YoY
EPS (diluted)
$-2.10
FY2025+10% YoY
Free cash flow(?)
-$132.31M
FY2025-46% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Cabaletta Bio, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
D.E. ShawQ2 2026open$3.31$3.29-1%
Point72 Asset ManagementQ1 2026open$2.96$3.29+11%
Citadel AdvisorsQ2 2025Q2 2026$1.81$3.31+83%
AQR Capital ManagementQ2 2025Q4 2025$1.81$2.31+28%
Renaissance TechnologiesQ1 2025open$2.70$3.29+22%
D.E. ShawQ4 2024Q2 2025$3.78$1.81-52%
Point72 Asset ManagementQ4 2024Q2 2025$3.78$1.81-52%
Citadel AdvisorsQ3 2024Q1 2025$4.38$2.71-38%
Two Sigma InvestmentsQ3 2024open$4.38$3.29-25%
Millennium ManagementQ3 2024open$4.38$3.29-25%
Duquesne Family OfficeQ2 2024Q3 2024$0.00—+0%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.